title: [The French preliminary experience of the use of a seed-projector for exclusive iodine 125 prostate brachytherapy: feasibility and acute toxicity].
abstract: OBJECTIVE
  To analyse a new technique for prostate brachytherapy with permanent Iodine implants characterized by the use of a seed projector after a 3D dosimetric peroperative treatment planning (FIRST technique).
  
  
  METHODS
  395 patients have been treated in France with this technique in six radiotherapy centres between November 2002 and December 2005 for a localized prostate cancer.
  
  
  RESULTS
  Thirteen patients (3.3%) developped a urinary retention, and respectively 7.8 and 26.5% an acute RTOG grade 3 and 2 toxicity. The 6-weeks IPSS score was equal or lower to 15 in 73% with a 11 median IPSS value. A failure of the loading with the seed-projector, leading to a manual loading of the seeds, occurred in 9 patients (2.3%) in two centres, directly related to the loading procedure with the seed-projector in 5 cases. The median duration of the procedure was reduced by 30 minutes for the patients treated in 2005.
  
  
  CONCLUSIONS
  This multicenter study establishes the feasibility of the routine use of a seed projector for permanent iodine 125 prostate implants with an initial tolerance similar to the best results published for other implants techniques.
authors.affiliation: Centre Léon-Bérard, 28, rue Laënnec, 69373 Lyon, France. pommier@lyon.fnclcc.fr
authors.forename: P
authors.initials: P
authors.lastname: Pommier
authors.forename: M
authors.initials: M
authors.lastname: Delannes
authors.forename: O
authors.initials: O
authors.lastname: LeFloch
authors.forename: V
authors.initials: V
authors.lastname: Bernier
authors.forename: M-H
authors.initials: MH
authors.lastname: Baron
authors.forename: L
authors.initials: L
authors.lastname: Thomas
authors.forename: C
authors.initials: C
authors.lastname: Malet
authors.forename: J
authors.initials: J
authors.lastname: Bonnet
authors.forename: P
authors.initials: P
authors.lastname: Louisot
authors.forename: P
authors.initials: P
authors.lastname: Aletti
authors.forename: O
authors.initials: O
authors.lastname: Goubard
authors.forename: A
authors.initials: A
authors.lastname: Chemin
authors.forename: F
authors.initials: F
authors.lastname: Chirat
authors.forename: S
authors.initials: S
authors.lastname: Lebivic
authors.forename: X
authors.initials: X
authors.lastname: Montbarbon
authors.forename: J-M
authors.initials: JM
authors.lastname: Bachaud
authors.forename: L
authors.initials: L
authors.lastname: Votron
authors.forename: O
authors.initials: O
authors.lastname: Lasbareilles
authors.forename: O
authors.initials: O
authors.lastname: Desmettre
authors.forename: G
authors.initials: G
authors.lastname: Bringeon
authors.forename: F
authors.initials: F
authors.lastname: Gassa
authors.forename: D
authors.initials: D
authors.lastname: Peiffert
mesh_terms: D001918:Brachytherapy / Q000009:adverse effects* / Q000379:methods*; D005240:Feasibility Studies; D005500:Follow-Up Studies; D005602:France; D006801:Humans; D021621:Imaging, Three-Dimensional; D007457:Iodine Radioisotopes / Q000008:administration & dosage*; D008297:Male; D009367:Neoplasm Staging; D011467:Prostate / Q000473:pathology; D017430:Prostate-Specific Antigen / Q000097:blood; D011471:Prostatic Neoplasms / Q000175:diagnosis / Q000473:pathology / Q000532:radiotherapy*; D011880:Radiotherapy Planning, Computer-Assisted; D013997:Time Factors; D016055:Urinary Retention / Q000209:etiology
chemical_list: D007457:Iodine Radioisotopes; D017430:Prostate-Specific Antigen